ALK Upgrades Its Full-Year Revenue and Earnings Outlook
ALK (ALKB:DC / OMX: ALK B / AKBLF) has announced an upgrade to its financial outlook for the full year. This decision reflects the company's current performance and the expected results for the remainder of the financial year.
Revenue Growth Expectations
Recent projections indicate that revenue is now expected to increase by 14-16% in local currencies, up from the previous estimate of 12-15%. This optimistic outlook is largely due to strong sales of tablets and both injection- and drop-based allergy immunotherapy products (SCIT/SLIT-drops) across Europe.
Factors Influencing Sales Growth
The impressive sales growth anticipated for 2024 is driven by several extraordinary factors. A significant rise in the number of new patients starting treatment over the past year has been crucial. Additionally, enhanced pricing strategies and rebate adjustments have positively impacted sales figures, along with competitive dynamics in key markets.
Earnings Outlook Upgrade
ALK's upgrade in its full-year earnings forecast is primarily due to the expected higher sales growth. It is important to note that the earnings outlook still accounts for one-off costs of approximately DKK 60 million related to previously announced optimization efforts.
Upcoming Financial Reporting
The Q2 report, which was initially scheduled for release, will now be published later today. The timing for the previously announced presentation for investors and analysts remains unchanged and will take place as originally planned.
Company Overview
ALK-Abelló A/S is a prominent global specialty pharmaceutical company that focuses specifically on allergies and allergic asthma. The company offers a range of allergy immunotherapy treatments and other products designed for patients managing allergies, as well as services aimed at allergy professionals.
Company Workforce and Market Position
Based in Hørsholm, Denmark, ALK employs around 2,900 individuals worldwide. Being publicly listed on Nasdaq Copenhagen enhances its visibility and operational capabilities within the pharmaceutical industry.
Contact Information
If you have any questions or need more information about ALK, please contact the following individuals:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
Frequently Asked Questions
What prompted ALK to upgrade its revenue outlook?
The upgrade was mainly due to strong sales of allergy immunotherapy products and a high number of new patients beginning treatment.
How much is ALK expecting its revenue to grow?
ALK is anticipating revenue growth of 14-16% in local currencies, an adjustment from the earlier estimate of 12-15%.
What are the expected earnings for the financial year?
The earnings outlook remains optimistic, contingent on expected sales growth, while accounting for one-off costs related to optimization efforts.
When will ALK's Q2 report be published?
The Q2 report will be released later today, rather than on the previously scheduled date.
Who should be contacted for investor relations at ALK?
For investor relations, Per Plotnikof can be contacted at +45 4574 7527 or +45 2261 2525.
